Literature DB >> 31672299

Treatment of Differentiated Thyroid Carcinomas.

Melissa G Lechner1, Stephanie Smooke Praw2, Trevor E Angell3.   

Abstract

Differentiated thyroid cancer (DTC) is the most common thyroid cancer and is frequently encountered in clinical practice. The incidence of DTC has increased significantly over the past three decades. Surgical resection, radioactive iodine (RAI), and levothyroxine suppression therapy remain the primary modalities for DTC treatment. Active surveillance for low-risk thyroid cancer may be an alternative to immediate surgery for appropriately selected patients. Patient characteristics influence treatment selection and intensity. In the subset of patients with progressive distant metastatic disease, not amenable to treatment with surgery or RAI, novel agents, including targeted therapies and immunotherapy, should be considered.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Active surveillance; BRAF; Differentiated thyroid cancer; Dynamic risk stratification; Radioactive iodine; Surgery; Treatment; Tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2019        PMID: 31672299     DOI: 10.1016/j.path.2019.08.003

Source DB:  PubMed          Journal:  Surg Pathol Clin        ISSN: 1875-9157


  2 in total

Review 1.  Total thyroidectomy vs. lobectomy in differentiated thyroid cancer: is there a reasonable size cut-off for decision? A narrative review.

Authors:  Daniele Barbaro; Giancarlo Basili; Gabriele Materazzi
Journal:  Gland Surg       Date:  2021-07

2.  A multicenter, prospective study to observe the initial management of patients with differentiated thyroid cancer in China (DTCC study).

Authors:  Jie Ming; Jing-Qiang Zhu; Hao Zhang; Hui Sun; Jun Wang; Ruo-Chuan Cheng; Lei Xie; Xing-Rui Li; Wen Tian; Tao Huang
Journal:  BMC Endocr Disord       Date:  2021-10-21       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.